Audio recording of earnings call on Q2 and half-year results put on company website
Evonile Pharma (formerly Novartis India) held its earnings call on Wednesday, November 04, 2026, in virtual mode.
By ScoutQuest · · 1 min read
- Earnings Call Date
- Wednesday, November 04, 2026
- Results Period Covered
- quarter and half-year ended September 30, 2026
- Call Mode
- virtual mode
What this update says
Evonile Pharma Limited, earlier known as Novartis India Limited, has informed BSE that it held an earnings call on Wednesday, November 04, 2026, in virtual mode. The call was about the unaudited financial results for the quarter and half-year ended September 30, 2026.
Recording now available
- The audio of the call has been uploaded on the company website at evonilepharma.com/earnings-call/
- The presentation used for the call was submitted to BSE on November 03, 2026
What was confirmed about the call
The company states that no unpublished price sensitive information was shared or discussed during the call. This is a standard assurance given when such calls are held, so that all investors get the same information at the same time.
Why this may matter to you
An earnings call is where the management walks through the results and takes questions. For a retail investor, the audio recording is a way to hear that discussion directly, in the management's own words, rather than relying only on the numbers in the results.
- If you hold or track the stock, the recording lets you check how the company explained its numbers for the quarter and half-year ended September 30, 2026.
- The call is already over; this intimation is about making its recording available, not about new decisions or announcements.
What this update is, in simple terms
This is an intimation that the recording of an investor call has been put up on the website. It is an information-sharing step; the financial results and the presentation referred to were part of the same results exercise.
Also from Evonile Pharma
Evonile Pharma reports first results after change of control
3 Nov 2026
Evonile Pharma Q2 and H1 FY27 results update: Q2 revenue down 38% YoY after business-model change
3 Nov 2026
Board approves unaudited results for September 2026 quarter; auditors' limited review unmodified
3 Nov 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.